Suchergebnisse - "Yeh, Teng-Kuang"

PubPharm (15)

1

Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer

enthalten in: Journal of medicinal chemistry | 2023

von Li, M. | Coumar, M. | Lin, S. | +16

2

Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization

enthalten in: European journal of medicinal chemistry | 2021

von Li, M. | Lin, W. | Wang, P. | +10

3

Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model

enthalten in: Journal of medicinal chemistry | 2021

von Lee, K. | Yen, W. | Lin, W. | +12

4

Discovery and Synthesis of a Pyrimidine-Based Aurora Kinase Inhibitor to Reduce Levels of MYC Oncoproteins

enthalten in: Journal of medicinal chemistry | 2021

von Chi, Y. | Yeh, T. | Ke, Y. | +17

5

Drug-like property optimization : Discovery of orally bioavailable quinazoline-based multi-targeted kinase inhibitors

enthalten in: Bioorganic chemistry | 2020

von Lin, S. | Chang, C. | Coumar, M. | +14

6

Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia

enthalten in: Journal of medicinal chemistry | 2019

von Lin, W. | Wu, S. | Yeh, T. | +25

7

Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer

enthalten in: Journal of medicinal chemistry | 2019

von Lin, S. | Chang Hsu, Y. | Peng, Y. | +17

8

Discovery of Conformational Control Inhibitors Switching off the Activated c-KIT and Targeting a Broad Range of Clinically Relevant c-KIT Mutants

enthalten in: Journal of medicinal chemistry | 2019

von Wu, T. | Lin, W. | Tsai, H. | +18

9

Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors : Rational design, synthesis, in vitro and in vivo evaluation

enthalten in: Oncotarget | 2016

von Hsu, Y. | Coumar, M. | Wang, W. | +22

10

Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations

enthalten in: European journal of medicinal chemistry | 2015

von Chen, C. | Hsu, J. | Lin, W. | +15